Moreover, suppression of mTORC1-dependent translation has been shown to reduce the levels of MCL-1 and sensitize various cancer cells, including ABT-199 resistant DLBCL, to BCL-2 antagonists [10-13]. This evidence concerns the gene MCL1 and diffuse large B-cell lymphoma.